Skip to main content

2015 PCSS-O Archived Webinars - CME

The American Academy of Pain Medicine (AAPM) provides enduring material (archived webinars) and offers continuing medical education (CME) for physicians. Successful completion requires that participants view and participate, and complete an online post-test and evaluation. Participants receive their CME certificates after they submit their evaluations online.

Accreditation:
The American Academy of Pain Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
The American Academy of Pain Medicine designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*Best Practices: Eight Principles for Safer Opioid Prescribing for Pain Management = 1 Credit
*Guide to Aberrant Drug-Related Behavior When Prescribing Opioids for Pain Management = 1 Credit
*Responsible Prescribing of Methadone for Pain Management: Safety First = 1 Credit


Funding:
Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Opioid Therapies (grant no. 1H79TI025595) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For more information visit: www.pcss-o.org
For questions email: pcss-o@aaap.org

Disclaimer:
The material presented in this activity represents the opinion of the authors/faculty and not necessarily the view of the American Academy of Pain Medicine.

Faculty/Planner Disclosures & Policy:
It is the policy of AAPM to plan and implement educational activities in accordance with ACCME’s Essential Areas and Elements to ensure balance, independence, objectivity, and scientific rigor. All program faculty and planners are required to disclose all financial relationships they may have or have had within the last 12 months with commercial interests whose products or services are related to the subject matter of the presentation. Any real or apparent conflicts of interest will be resolved prior to the presentation. All confirmed faculty disclosure information will be made available to participants prior to the activity. Faculty will also be expected to disclose this information to the audience both verbally and in print (slide presentation) at the beginning of each presentation. Faculty members are also required to inform program participants if any unlabeled uses of products regulated by the U.S. Food and Drug Administration will be discussed.

Target Audience/Program Overview:
This course is for a primary audience of physicians whose scope of practice is targeted at the practice of pain medicine, as well as a secondary audience of nonphysician
healthcare clinicians who are part of the pain management team.

Expert Educational Design:
This education initiative was planned and facilitated by leaders from the American Academy of Pain Medicine (AAPM). AAPM is the leading medical association representing physicians committed to advancing the emerging science and practice of pain medicine. This comprehensive pain medicine curriculum is designed to improve access to quality, evidenced- based multidisciplinary pain care across the healthcare continuum.

Disclosure information appears below.

Planners:
Lynn R. Webster, MD
Vice President of Scientific Affairs
PRA International
Salt Lake City, UT
Acura Pharmaceuticals (honorarium—consultant/travel expenses);
AstraZeneca (honorarium—consultant/travel expenses);
BioDelivery Sciences International (honorarium—consultant/travel expenses);
Bristol-Myers Squibb (BMS) (travel expenses);
CVS Caremark (honorarium—consultant);
Depomed (honorarium—advisory board/travel expenses);
Egalet (honorarium—advisory board);
Grunenthal USA (honorarium—consultant/travel expenses);
Inspirion Pharmaceuticals (honorarium—advisory board/travel expenses);
Insys Therapeutics (honorarium—advisory board/travel expenses);
Jazz Pharmaceuticals (travel expenses);
Kaleo (honorarium—advisory board/travel expenses);
Mallinckrodt Pharmaceuticals (honorarium—consultant/honorarium—advisory board/travel expenses);
Nektar Therapeutics (travel expenses);
Nevro Corporation (honorarium—consultant/travel expenses);
Orexo Pharmaceuticals (travel expenses);
Signature Therapeutics (honorarium—advisory board);
Synchrony Healthcare (honorarium—consultant);
Teva Pharmaceuticals (honorarium—advisory board/travel expenses)
Travena (honorarium—advisory board/travel expenses)


Vitaly Gordin, MD
Director of Pain Division
Penn State Hershey Medical Center
Hershey, PA
No relevant financial relationships

Jennifer Westlund, MSW
Director of Education
American Academy of Pain Medicine
No relevant financial relationships

Angela Casey
VP, Medical Director
PharmaCom Group
No relevant financial relationships

Faculty:
Lynn R. Webster, MD
Vice President of Scientific Affairs
PRA International
Salt Lake City, UT
Acura Pharmaceuticals (honorarium—consultant/travel expenses);
AstraZeneca (honorarium—consultant/travel expenses);
BioDelivery Sciences International (honorarium—consultant/travel expenses);
Bristol-Myers Squibb (BMS) (travel expenses);
CVS Caremark (honorarium—consultant);
Depomed (honorarium—advisory board/travel expenses);
Egalet (honorarium—advisory board);
Grunenthal USA (honorarium—consultant/travel expenses);
Inspirion Pharmaceuticals (honorarium—advisory board/travel expenses);
Insys Therapeutics (honorarium—advisory board/travel expenses);
Jazz Pharmaceuticals (travel expenses);
Kaleo (honorarium—advisory board/travel expenses);
Mallinckrodt Pharmaceuticals (honorarium—consultant/honorarium—advisory board/travel expenses);
Nektar Therapeutics (travel expenses);
Nevro Corporation (honorarium—consultant/travel expenses);
Orexo Pharmaceuticals (travel expenses);
Signature Therapeutics (honorarium—advisory board);
Synchrony Healthcare (honorarium—consultant);
Teva Pharmaceuticals (honorarium—advisory board/travel expenses)
Travena (honorarium—advisory board/travel expenses)